PTC Therapeutics, Inc. Intangible Assets, Net (Excluding Goodwill)
PTC Therapeutics, Inc. (PTCT) had Intangible Assets, Net (Excluding Goodwill) of $402.93 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Excluding Goodwill, after Accumulated Amortization
us-gaap:IntangibleAssetsNetExcludingGoodwill · last filed 2026-07-30
- 2026-06-30: Intangible Assets, Net (Excluding Goodwill) $402.93M.
- 2026-03-31: Intangible Assets, Net (Excluding Goodwill) $380.68M.
- 2025-12-31: Intangible Assets, Net (Excluding Goodwill) $388.75M.
- 2025-09-30: Intangible Assets, Net (Excluding Goodwill) $396.47M.
| Period end | Intangible Assets, Net (Excluding Goodwill) |
|---|---|
| 2026-06-30 | $402.93M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $380.68M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $388.75M 10-Q · filed 2026-07-30 |
| 2025-09-30 | $396.47M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $143.81M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $118.45M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $118.79M 10-K · filed 2026-02-19 |
| 2024-09-30 | $330.37M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $329.88M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $330.04M 10-Q · filed 2024-04-25 |
| 2023-12-31 | $379.50M 10-K · filed 2025-02-27 |
| 2023-09-30 | $423.34M 10-Q · filed 2023-10-26 |
| 2023-06-30 | $451.63M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $686.21M 10-Q · filed 2023-04-27 |
| 2022-12-31 | $705.89M 10-K · filed 2024-02-29 |
| 2022-09-30 | $749.89M 10-Q · filed 2022-10-27 |
| 2022-06-30 | $760.15M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $763.66M 10-Q · filed 2022-05-03 |
| 2021-12-31 | $724.84M 10-K · filed 2023-02-21 |
| 2021-09-30 | $723.26M 10-Q · filed 2021-10-28 |
| 2021-06-30 | $717.08M 10-Q · filed 2021-07-29 |
| 2021-03-31 | $712.57M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $715.33M 10-K · filed 2022-02-22 |
| 2020-09-30 | $712.54M 10-Q · filed 2020-10-29 |
| 2020-06-30 | $708.81M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $705.29M 10-Q · filed 2020-04-30 |
| 2019-12-31 | $710.50M 10-K · filed 2021-02-25 |
| 2019-09-30 | $702.91M 10-Q · filed 2019-10-30 |
| 2019-06-30 | $702.73M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $694.96M 10-Q · filed 2019-05-02 |
| 2018-12-31 | $701.03M 10-K · filed 2020-03-02 |
| 2018-09-30 | $604.61M 10-Q · filed 2018-11-05 |
| 2018-06-30 | $126.29M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $127.56M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $132.99M 10-K · filed 2019-03-01 |
| 2017-09-30 | $138.42M 10-Q · filed 2017-11-02 |
| 2017-06-30 | $148.14M 10-Q · filed 2017-08-09 |
| 2016-12-31 | $0.00 10-K · filed 2018-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |